ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

KYMR Kymera Therapeutics Inc

33.27
0.25 (0.76%)
After Hours
Last Updated: 21:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kymera Therapeutics Inc NASDAQ:KYMR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 0.76% 33.27 31.65 41.25 33.8286 31.54 32.815 774,417 21:30:00

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28/08/2024 12:00pm

GlobeNewswire Inc.


Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart


From Mar 2024 to Mar 2025

Click Here for more Kymera Therapeutics Charts.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:

  • Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET;
  • Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 5 at 3:20 p.m. ET;
  • H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 9 at 8:00 a.m. ET; and
  • 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY on September 17 at 11:30 a.m. ET.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.

About Kymera TherapeuticsKymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.

Investor and Media Contact:Justine KoenigsbergVice President, Investor Relationsinvestors@kymeratx.commedia@kymeratx.com857-285-5300 

1 Year Kymera Therapeutics Chart

1 Year Kymera Therapeutics Chart

1 Month Kymera Therapeutics Chart

1 Month Kymera Therapeutics Chart

Your Recent History

Delayed Upgrade Clock